Emil Kuriakose
CIK 1892413 · Chief Medical Officer · last filed 2026-05-05
Emil Kuriakose is a Chief Medical Officer who has filed 15 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for TERN, was dated May 5, 2026. Across all open-market trades the lifetime net is −$133.3K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TERN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Chief Medical Officer | 0 | $52.95 | $0 | -$133.3K | 10 | 2026-05-05 |
| Calithera Biosciences, Inc. (CALA) Delisted | CHIEF MEDICAL OFFICER | 3,539 | $0.00 | $1 | $0 | 5 | 2023-01-25 |
Recent Filings
15 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-05 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Mixed | −106,515 | -$5.65M | EDGAR |
| 2026-04-02 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Sell (S) | −942 | -$49.7K | EDGAR |
| 2026-01-16 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Grant (A) | +56,250 | $0 | EDGAR |
| 2026-01-06 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Sell (S) | −1,155 | -$44.6K | EDGAR |
| 2025-10-02 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Sell (S) | −944 | -$7.4K | EDGAR |
| 2025-07-03 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Sell (S) | −853 | -$3.6K | EDGAR |
| 2025-04-02 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Sell (S) | −952 | -$2.4K | EDGAR |
| 2025-02-03 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-01-06 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Sell (S) | −4,481 | -$25.6K | EDGAR |
| 2024-12-16 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.